Sarepta Therapeutics, Inc. (SRPT)
SRPT Stock Price Chart
Explore Sarepta Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SRPT price movements and trends.
SRPT Company Profile
Discover essential business fundamentals and corporate details for Sarepta Therapeutics, Inc. (SRPT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Jun 1997
Employees
1.37K
Website
https://www.sarepta.comCEO
Douglas S. Ingram
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT Financial Timeline
Browse a chronological timeline of Sarepta Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is $0.12, while revenue estimate is $349.73M.
Earnings released on 6 Aug 2025
EPS came in at $2.02 surpassing the estimated $1.11 by +81.98%, while revenue for the quarter reached $611.09M , beating expectations by +78.19%.
Earnings released on 6 May 2025
EPS came in at -$3.42 falling short of the estimated $0.35 by -1.08K%, while revenue for the quarter reached $744.86M , beating expectations by +0.71%.
Earnings released on 26 Feb 2025
EPS came in at $1.50 surpassing the estimated $1.38 by +8.70%, while revenue for the quarter reached $658.41M , beating expectations by +4.34%.
Earnings released on 6 Nov 2024
EPS came in at $0.62 surpassing the estimated -$0.06 by +1.14K%, while revenue for the quarter reached $467.17M , beating expectations by +14.74%.
Earnings released on 7 Aug 2024
EPS came in at $0.07 surpassing the estimated $0.01 by +1.20K%, while revenue for the quarter reached $362.93M , missing expectations by -7.98%.
Earnings released on 1 May 2024
EPS came in at $0.73 surpassing the estimated $0.10 by +625.65%, while revenue for the quarter reached $413.46M , beating expectations by +8.94%.
Earnings released on 28 Feb 2024
EPS came in at $0.47 surpassing the estimated $0.01 by +3.08K%, while revenue for the quarter reached $396.78M , beating expectations by +2.84%.
Earnings released on 1 Nov 2023
EPS came in at -$0.46 surpassing the estimated -$1.66 by +72.29%, while revenue for the quarter reached $331.82M , missing expectations by -8.63%.
Earnings released on 2 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$1.89 by +85.71%, while revenue for the quarter reached $261.24M , beating expectations by +0.65%.
Earnings released on 2 May 2023
EPS came in at -$0.97 surpassing the estimated -$1.46 by +33.56%, while revenue for the quarter reached $253.50M , beating expectations by +4.77%.
Earnings released on 28 Feb 2023
EPS came in at -$1.24 surpassing the estimated -$1.28 by +3.13%, while revenue for the quarter reached $258.43M , beating expectations by +3.21%.
Earnings released on 2 Nov 2022
EPS came in at -$2.94 falling short of the estimated -$1.21 by -142.98%, while revenue for the quarter reached $230.27M , missing expectations by -1.81%.
Earnings released on 2 Aug 2022
EPS came in at -$2.65 falling short of the estimated -$1.07 by -147.66%, while revenue for the quarter reached $233.49M , beating expectations by +5.74%.
Earnings released on 4 May 2022
EPS came in at -$1.20 surpassing the estimated -$1.35 by +11.11%, while revenue for the quarter reached $210.83M , beating expectations by +2.13%.
Earnings released on 1 Mar 2022
EPS came in at -$1.42 surpassing the estimated -$1.51 by +5.96%, while revenue for the quarter reached $201.46M , beating expectations by +1.76%.
Earnings released on 3 Nov 2021
EPS came in at -$0.60 surpassing the estimated -$1.86 by +67.74%, while revenue for the quarter reached $189.41M , missing expectations by -33.76%.
Earnings released on 4 Aug 2021
EPS came in at -$1.02 surpassing the estimated -$1.03 by +0.97%, while revenue for the quarter reached $164.09M , beating expectations by +0.88%.
Earnings released on 5 May 2021
EPS came in at -$2.10 falling short of the estimated -$2.01 by -4.48%, while revenue for the quarter reached $146.93M , missing expectations by -1.49%.
Earnings released on 1 Mar 2021
EPS came in at -$2.40 falling short of the estimated -$2.00 by -20.00%, while revenue for the quarter reached $145.14M , missing expectations by -0.79%.
Earnings released on 5 Nov 2020
EPS came in at -$2.50 falling short of the estimated -$1.89 by -32.28%, while revenue for the quarter reached $143.92M , beating expectations by +46.20%.
SRPT Stock Performance
Access detailed SRPT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.